This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
O’Donnell MR . Blood group Incompatibilities and hemolytic complications of hematopoietic cell transplantation. In: Appelbaum FR, Forman SJ, Negrin RS, Blume KG (eds). Thomas’ Hematopoietic Cell Transplantation, 4th edn, Wiley-Blackwell: Chichester, West Sussex, UK, 2008, pp 1219–1225.
Mielcarek M, Leisenring W, Torok-Storb B, Storb R . Graft-versus-host disease and donor-directed hemagglutinin titers after ABO-mismatched related and unrelated marrow allografts: evidence for a graft-versus-plasma cell effect. Blood 2000; 96: 1150–1156.
Gmur JP, Burger J, Schaffner A, Neftel K, Oelz O, Frey D et al. Pure red cell aplasia of long duration complicating major ABO-incompatible bone marrow transplantation. Blood 1990; 75: 290–295.
Fang B, Song Y, Li N, Li J, Han Q, Zhao RC . Mesenchymal stem cells for the treatment of refractory pure red cell aplasia after major ABO-incompatible hematopoietic stem cell transplantation. Ann Hematol 2009; 88: 261–266.
Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC . Multiple myeloma. Lancet 2009; 374: 324–339.
Kane RC, Dagher R, Farrell A, Ko CW, Sridhara R, Justice R et al. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 2007; 13: 5291–5294.
Carson KR, Beckwith LG, Mehta J . Successful treatment of IgM-mediated autoimmune hemolytic anemia with bortezomib. Blood 2010; 115: 915.
Acknowledgements
We thank Dr Jayesh Mehta (The Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, USA) and Dr Rainer Storb (Fred Hutchinson Cancer Research Center, University of Washington, Seattle, USA) for their invaluable advice given in the management of this case.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Poon, LM., Koh, L. Successful treatment of isohemagglutinin-mediated pure red cell aplasia after ABO-mismatched allogeneic hematopoietic cell transplant using bortezomib. Bone Marrow Transplant 47, 870–871 (2012). https://doi.org/10.1038/bmt.2011.176
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2011.176
This article is cited by
-
Successful treatment of refractory pure red cell aplasia in major ABO-mismatched allogeneic hematopoietic stem cell transplant with single agent Ibrutinib
Bone Marrow Transplantation (2022)
-
Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question
Bone Marrow Transplantation (2021)